Figure 1: Western blot analysis using CCNE1 mAb against human CCNE1 (AA: 307-410) recombinant protein. (Expected MW is 37.5 kDa)
Mouse Monoclonal Antibody to CCNE1

Mouse Monoclonal Antibody to CCNE1


Regular price $341.00 $290.00 You Pay

Supplier: ProMab Technologies
Type of Product: Monoclonal Antibody
Description: The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK2, whose activity is required for cell cycle G1/S transition. This protein accumulates at the G1-S phase boundary and is degraded as cells progress through S phase. Overexpression of this gene has been observed in many tumors, which results in chromosome instability, and thus may contribute to tumorigenesis. This protein was found to associate with, and be involved in, the phosphorylation of NPAT protein (nuclear protein mapped to the ATM locus), which participates in cell-cycle regulated histone gene expression and plays a critical role in promoting cell-cycle progression in the absence of pRB. Two alternatively spliced transcript variants of this gene, which encode distinct isoforms, have been described. Two additional splice variants were reported but detailed nucleotide sequence information is not yet available.
Application: ELISA: 1/10000; WB: 1/500 - 1/2000; FCM: 1/200 - 1/400
Size: 100 ul, 1mg/ml
Species Reactivity: Human; Mouse
Clone: 5F8C5;
Isotype: Mouse IgG1
Immunogen: Purified recombinant fragment of human CCNE1 (AA: 307-410) expressed in E. Coli.
Formulation: Purified antibody in PBS with 0.05% sodium azide.
MW: 47kDa
Storage: 4C; -20C for long term storage
Spplier link:
Reference: 1. Cancer Res. 2010 Jun 15;70(12):5074-84. ; 2. Cancer. 2010 Jun 1;116(11):2621-34.